Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Time to Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) gapped up prior to trading on Monday . The stock had previously closed at $9.64, but opened at $9.98. Gyre Therapeutics shares last traded at $9.79, with a volume of 25,129 shares traded.

Gyre Therapeutics Price Performance

The stock’s 50 day moving average price is $12.97 and its 200 day moving average price is $12.60.

Institutional Trading of Gyre Therapeutics

A number of large investors have recently bought and sold shares of GYRE. Bank of New York Mellon Corp acquired a new position in shares of Gyre Therapeutics in the 2nd quarter valued at about $218,000. Rhumbline Advisers acquired a new position in Gyre Therapeutics in the second quarter valued at approximately $123,000. WINTON GROUP Ltd bought a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $220,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter worth approximately $166,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after acquiring an additional 90,557 shares in the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.